Status and phase
Conditions
Treatments
About
Continuing high dose clopidogrel treatment after elective PCI decreased adverse cardiac events in patients with clopidogrel resistance
Full description
Aim:
Primary objective:
Secondary objective:
Study central:
Bursa Postgraduate Hospital, Cardiology Clinic
Study population:
we planned to enrol 180 patients. 50% of patients without clopidogrel resistance (control group: 90 patients) 50% have clopidogrel resistance. Than we randomise the patients (with clopidogrel resistance) in two groups (group 1:45 patients (75mg/day), group 2:45 patients (150mg/day))
inclusion criteria:
Exclusion criteria:
Study works:
Write case report form for all patients
Control for inclusion criteria.
Evaluate the clopidogrel and ASA resistance with VerifyNow kit. Than randomised the patients.
Demographic data (age, gender)
Height, weight, BMI and GFR
Risk factors
laboratory data (biochemical and hematologic)
Medication history
Echocardiographic data
Angiographic data
PCI data(vessel diameter, stent diameter, lesion and stent length, performed PTCA or not, etc)
Note complication (MACE, bleeding, hematoma etc)
4 weeks later note the first control data and re assess the clopidogrel resistance with VerifyNow kit in patients groups 1 and 2.
Six months later note the second control data.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
192 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal